丹麦制药公司诺和诺德周五表示，由于一家生产设施正在进行整改工作，美国FDA已延长对其实验性A型血友病药物的审查。
The US FDA has extended its review of Novo Nordisk's experimental hemophilia A drug due to ongoing remediation work at a manufacturing facility, the Danish drugmaker said on Friday.
路透社
美国FDA因设施问题延长对诺和诺德血友病药物的审查US FDA extends review of Novo Nordisk's hemophilia drug over facility issues
点「原文对照」整页切到原文，或双击某段只看那段的原文。